scholarly article | Q13442814 |
P2093 | author name string | F Lin | |
E Vittinghoff | |||
C N Pellegrini | |||
G M Marcus | |||
S B Hulley | |||
P2860 | cites work | Atherosclerosis — An Inflammatory Disease | Q26776972 |
New-onset atrial fibrillation: sex differences in presentation, treatment, and outcome | Q28183679 | ||
Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials | Q28194551 | ||
Cellular antioxidant effects of atorvastatin in vitro and in vivo | Q30809431 | ||
Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data | Q31137007 | ||
Interleukin-6 and atrial fibrillation in patients with coronary artery disease: data from the Heart and Soul Study | Q31143614 | ||
Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators | Q33863941 | ||
A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study | Q34225539 | ||
Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors | Q34463540 | ||
Inflammation as a risk factor for atrial fibrillation | Q34543274 | ||
Lifetime risk for development of atrial fibrillation: the Framingham Heart Study | Q34550202 | ||
Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis | Q34558240 | ||
Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee | Q34595917 | ||
Histological substrate of atrial biopsies in patients with lone atrial fibrillation | Q34742809 | ||
Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction. | Q35187745 | ||
Regional left atrial voltage in patients with atrial fibrillation | Q35792612 | ||
Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study | Q36255692 | ||
Association of statin therapy and the risk of atrial fibrillation in patients with a permanent pacemaker. | Q36516762 | ||
Women and coronary disease | Q37033746 | ||
Statins and polyunsaturated fatty acids for treatment of atrial fibrillation | Q37038371 | ||
Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials | Q37092392 | ||
Age and gender influences on rate and duration of paroxysmal atrial fibrillation. | Q43796912 | ||
Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. | Q43841962 | ||
C-reactive protein and paroxysmal atrial fibrillation: evidence of the implication of an inflammatory process in paroxysmal atrial fibrillation | Q43854958 | ||
Observational study on the beneficial effect of preoperative statins in reducing atrial fibrillation after coronary surgery | Q44321367 | ||
The effects of statins and renin-angiotensin system blockers on atrial fibrillation recurrence following antral pulmonary vein isolation | Q44351940 | ||
NOVACODE serial ECG classification system for clinical trials and epidemiologic studies | Q44369384 | ||
Risk for systemic embolization of atrial fibrillation without mitral stenosis | Q44539669 | ||
Analysis of pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion | Q44799248 | ||
Statin use is associated with a reduction in atrial fibrillation after noncardiac thoracic surgery independent of C-reactive protein | Q44916516 | ||
Statin use before by-pass surgery decreases the incidence and shortens the duration of postoperative atrial fibrillation | Q44990990 | ||
Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs | Q45101331 | ||
Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. | Q46000257 | ||
Effect of C-reactive protein reduction on paroxysmal atrial fibrillation | Q46807080 | ||
Effects of statin therapy on preventing atrial fibrillation in coronary disease and heart failure | Q46884911 | ||
Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery | Q46966857 | ||
Sex-based differences in the effect of intra-arterial treatment of stroke: analysis of the PROACT-2 study | Q48455009 | ||
Statin use and recurrence of atrial fibrillation after successful cardioversion. | Q50659655 | ||
Effects of gender on cardiac arrhythmias. | Q50878391 | ||
Downregulation of Endocardial Nitric Oxide Synthase Expression and Nitric Oxide Production in Atrial Fibrillation | Q60154495 | ||
Recurrence of paroxysmal atrial fibrillation or flutter after successful cardioversion in patients with normal left ventricular function | Q70595101 | ||
Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S) | Q71774511 | ||
Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications | Q72566134 | ||
C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation | Q77337410 | ||
Sex-based differences in the effect of digoxin for the treatment of heart failure | Q78455630 | ||
Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study | Q79137152 | ||
Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion | Q79322759 | ||
Therapy with angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and statins: no effect on ablation outcome after ablation of atrial fibrillation | Q79438250 | ||
The role of the post-cardioversion time course of hs-CRP levels in clarifying the relationship between inflammation and persistence of atrial fibrillation | Q80492097 | ||
Inflammation and atrial fibrillation: cause or effect? | Q80492759 | ||
Comparison of frequency of new-onset atrial fibrillation or flutter in patients on statins versus not on statins presenting with suspected acute coronary syndrome | Q80692313 | ||
Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting | Q82080303 | ||
Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion | Q83297067 | ||
P433 | issue | 9 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | atrial fibrillation | Q815819 |
P304 | page(s) | 704-708 | |
P577 | publication date | 2009-01-28 | |
P1433 | published in | Heart | Q856338 |
P1476 | title | Statin use is associated with lower risk of atrial fibrillation in women with coronary disease: the HERS trial | |
P478 | volume | 95 |
Q34682939 | Antiarrhythmic effects of simvastatin in canine pulmonary vein sleeve preparations |
Q37679127 | Atrial fibrillation and bisphosphonate therapy |
Q26853571 | Benefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians - a population with the highest risk of premature coronary artery disease & diabetes |
Q36701732 | N-3 polyunsaturated fatty acids to prevent atrial fibrillation: updated systematic review and meta-analysis of randomized controlled trials |
Q37638445 | Primary and secondary prevention of atrial fibrillation with statins and polyunsaturated fatty acids: review of evidence and clinical relevance |
Q33984012 | Statin Therapy for Primary Prevention of Atrial Fibrillation: Guided by CHADS2/CHA2DS2VASc Score |
Q36540145 | Statins therapy can reduce the risk of atrial fibrillation in patients with acute coronary syndrome: a meta-analysis |
Q37602866 | Targeting inflammation and oxidative stress in atrial fibrillation: role of 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibition with statins. |
Q37543186 | Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a community-based study |
Q37846370 | Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention. |
Q37546133 | Upstream therapy of atrial fibrillation |
Search more.